药物涂层球囊在冠状动脉大血管原发病变中应用的研究进展  

Research progress of drug-coated balloon application in large de novo coronary artery lesions

作　　者：张峰[1] 陈欣[1] ZHANG Feng;CHEN Xin(Department of Cardiology,Tianjin First Center Hospital,Tianjin,300192,China)

机构地区：[1]天津市第一中心医院心脏科,天津300192

出　　处：《临床心血管病杂志》2020年第10期961-964,共4页Journal of Clinical Cardiology

摘　　要：药物涂层球囊(DCB)是球囊扩张术和药物涂层技术结合的产物。DCB既能将抑制再狭窄的药物输送释放至治疗段血管,又没有金属植入物,使"介入无植入"成为可能。已有多项临床研究验证了DCB在支架内再狭窄(ISR)治疗中的优越性。冠状动脉原发病变是指除支架内、桥血管病变的冠状动脉自身血管病变。对于冠状动脉大血管(一般定义为直径≥2.8 mm)的原发病变,植入药物洗脱支架(DES)仍是主要治疗手段。目前有多项研究对DCB在冠状动脉大血管原发病变中的应用做了尝试和评价,本文就此作一综述。Drug-coated balloon(DCB)is a combination of balloon dilatation and drug-coating technology.DCB not only can deliver the drug to the treated vessel,but also has no metal implant,which makes"leave nothing behind"possible.Several clinical studies have demonstrated the superiority of DCB in the treatment of in-stent restenosis.De novo coronary artery lesions refer to native coronary artery lesions except in-stent restenosis and bypass graft lesions.A large coronary artery is commonly defined as a vessel with a diameter≥2.8 mm.While drug-eluting stent implantation is still the primary therapeutic method for large de novo coronary artery lesions,many trials have tried and evaluated the application of DCB in large de novo coronary artery lesions.This article reviews this issue.

关 键 词：药物涂层球囊 冠状动脉大血管 原发病变 

分 类 号：R541.4[医药卫生—心血管疾病]